Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
A new study conducted by Baylor College of Medicine and presented at the American College of Cardiology Annual Scientific Session as well as the World Congress of Cardiology shows that an oral PCSK9 inhibitor called MK-0616...
Read Full NewsA phase 2a trial showed that NLX-112 was safe and well tolerated in patients with Parkinson disease, while also reducing levodopa-induced dyskinesia and motor symptoms, supporting further clinical development.
AskBio noted that AB-1009 also recently received fast track and orphan drug designations from the FDA.
Amlitelimab Effective, Safe for Atopic Dermatitis in Patients 12 Years and Older
1.
United States Lung Cancer Screening Rates Remain Low. s. in particular in the South.
2.
Mobile prostate cancer screening clinic can ID the disease in disadvantaged men
3.
PSMA PET Beats MRI in Prostate Cancer Staging Study
4.
After cancer: Study explores caring-healing modalities for survivors
5.
GLP-1 Drugs Linked to Lower Colorectal Cancer Risk for Diabetes Patients.
1.
Revolutionizing Cancer Treatment: ESMO's Updated Recommendations for Tumour NGS
2.
The Importance of Corrected Calcium Levels in Managing Health Conditions
3.
Methemoglobinemia in OR & ICU: Pathophysiology, Detection, and Management Review
4.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
5.
Understanding Granulosa Cell Tumors: Symptoms, Diagnosis, and Treatments"
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI
2.
Navigating the Complexities of Ph Negative ALL - Part XVI
3.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
4.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
5.
Navigating the Complexities of Ph Negative ALL - Part III
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge